Abstract
Cefotiam, a new cephalosporin, was evaluated in the treatment of lower respiratory tract infections in 29 patients. The bacteria isolated from the sputum of these patients included Streptococcus pneumoniae (31%), Klebsiella pneumoniae (31%), and Haemophilus influenzae (28%). Satisfactory response was observed in 90% of the patients. There were three treatment failures, two superinfections, and four colonizations with gram-negative organisms resistant to the drug. Superficial phlebitis was noted in two patients. The results of this study suggest that cefotiam is an effective and well-tolerated antibiotic for the treatment of lower respiratory tract infections due to susceptible organisms.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
- Lentino J. R., Stachowski M., Strikas R., Parrillo P. Comparative efficacy of cefotiam versus cephalothin in the therapy of skin and soft tissue infections. Antimicrob Agents Chemother. 1984 Jun;25(6):778–780. doi: 10.1128/aac.25.6.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Murray P. R., Washington J. A. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc. 1975 Jun;50(6):339–344. [PubMed] [Google Scholar]
- Nozaki Y., Imada A., Yoneda M. SCE-963, a new potent cephalosporin with high affinity for penicillin-binding proteins 1 and 3 of Escherichia coli. Antimicrob Agents Chemother. 1979 Jan;15(1):20–27. doi: 10.1128/aac.15.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ogawa M., Hama M., Kosaki G., Shimatani M., Suginaka H. Comparison of cefotiam and cefazolin activity against Gram-negative bacilli. J Antimicrob Chemother. 1979 Nov;5(6):681–685. doi: 10.1093/jac/5.6.681. [DOI] [PubMed] [Google Scholar]
- Tillotson J. R., Finland M. Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia. J Infect Dis. 1969 Jun;119(6):597–624. doi: 10.1093/infdis/119.6.597. [DOI] [PubMed] [Google Scholar]
- Tsuchiya K., Kida M., Kondo M., Ono H., Takeuchi M., Nishi T. SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1978 Oct;14(4):557–568. doi: 10.1128/aac.14.4.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tsuchiya K., Kondo M., Kita Y., Noji Y., Takeuchi M., Fugono T. Absorption, distribution and excretion of SCE-963, a new broad-spectrum cephalosporin, in mice, rats, rabbits and dogs. J Antibiot (Tokyo) 1978 Dec;31(12):1272–1282. doi: 10.7164/antibiotics.31.1272. [DOI] [PubMed] [Google Scholar]
- Watt B., Brown F. V. In-vitro activity of cefotiam against bacteria of clinical interest. J Antimicrob Chemother. 1982 Nov;10(5):391–395. doi: 10.1093/jac/10.5.391. [DOI] [PubMed] [Google Scholar]